Real-world infection risk in multiple sclerosis patients on long-term immunomodulatory treatments.

ABSTRACT:

Introduction

Numerous immunomodulatory treatments exist for multiple sclerosis (MS), including those that deplete immune cells (e.g. anti-CD20 medications), relocate immune cells (e.g. natalizumab, S1P modulators), or modulate immune subsets (e.g. fumarates). All disease-modifying treatments (DMTs) can increase infection risk which could worsen with prolonged use.

Methods

This is a retrospective, single-center, observational cohort study. We analyzed medical records of adult people with MS who took natalizumab, S1P modulators, fumarates or anti-CD20 medications for over two years between January 2013 and April 2021 at Yale. We identified severe infections (requiring hospitalization) and mild infections (identified through outpatient antibiotic prescriptions or chart referenc

SUBMITTER: Lambert CM 

PROVIDER: S-EPMC11869388 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature